Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2012; 18(12): 1357-1364
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Cisplatin group | Irinotecan group | Oxaliplatin group | Other group | P value | |
Clinical toxicity grade 3-4 | |||||
Nausea | 0 | 0 | 3 (14.3) | 0 | NS |
Vomiting | 2 (9.1) | 0 | 2 (9.5) | 1 (5.3) | NS |
Diarrhea | 1 (4.5) | 1 (5.6) | 0 | 0 | NS |
Fever | 0 | 4 (22.3) | 1 (4.8) | 1 (5.3) | NS |
Infection | 0 | 3 (16.7) | 3 (14.3) | 0 | NS |
Haematological toxicity grade 3-4 | |||||
Anemia | 0 | 1 (5.6) | 1 (4.8) | 0 | NS |
Neutropenia | 6 (27.3) | 6 (33.4) | 2 (9.5) | 0 | NS |
Thrombocytopenia | 1 (4.5) | 0 | 0 | 0 | NS |
- Citation: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364
- URL: https://www.wjgnet.com/1007-9327/full/v18/i12/1357.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i12.1357